

1-1-2012

## **Modulation of Inflammation and Oxidative Stress in Canine Chondrocytes**

David L. Dycus

Follow this and additional works at: <https://scholarsjunction.msstate.edu/td>

---

### **Recommended Citation**

Dycus, David L., "Modulation of Inflammation and Oxidative Stress in Canine Chondrocytes" (2012).  
*Theses and Dissertations*. 3175.  
<https://scholarsjunction.msstate.edu/td/3175>

This Graduate Thesis - Open Access is brought to you for free and open access by the Theses and Dissertations at Scholars Junction. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of Scholars Junction. For more information, please contact [scholcomm@msstate.libanswers.com](mailto:scholcomm@msstate.libanswers.com).

Modulation of inflammation and oxidative stress in canine chondrocytes

By

David Lee Dycus

A Thesis  
Submitted to the Faculty of  
Mississippi State University  
in Partial Fulfillment of the Requirements  
for the Degree of Master of Science  
in Veterinary Medical Science  
in the College of Veterinary Medicine

Mississippi State, Mississippi

December 2012

Copyright by  
David Lee Dycus  
2012

Modulation of inflammation and oxidative stress in canine chondrocytes

By

David Lee Dycus

Approved:

---

Jennifer L. Wardlaw  
Assistant Professor of Clinical Sciences  
(Director of Thesis)

---

Ron M. McLaughlin Jr.  
Professor of Clinical Sciences  
(Committee Member)

---

Carmelita G. Frondoza  
Committee Participant of Clinical Sciences  
(Committee Member)

---

Andrew J. Mackin  
Professor of Clinical Sciences  
(Graduate Coordinator)

---

Kent Hoblet  
Dean, College of Veterinary Medicine

Name: David Lee Dycus

Date of Degree: December 15, 2012

Institution: Mississippi State University

Major Field: Veterinary Medical Science

Major Professor: Dr. Jennifer Wardlaw

Title of Study: Modulation of inflammation and oxidative stress in canine chondrocytes

Pages in Study: 38

Candidate for Degree of Master of Science

Little research has focused on the involvement of oxidative stress as it relates to the pathophysiology of osteoarthritis (OA); while inflammation has been extensively studied. The present study evaluates the ability to modulate the response of canine chondrocytes to both inflammation and oxidative stress in an *in-vitro* model.

Chondrocytes were incubated and then stimulated to under-go oxidative stress by using hydrogen peroxide or inflammation using interleukin-1 beta and tumor necrosis factor alpha. For inhibition of oxidative stress an antioxidant, N-acetyl-cysteine, was used prior to induction with hydrogen peroxide in a subset of chondrocytes. Measures of oxidative stress were superoxide dismutase and reduced glutathione. Prostaglandin E2 was used as a measurement of inflammation. Chondrocytes responded appropriately to both oxidative stress and inflammation. The antioxidant N-acetyl-cysteine provided adequate protection against oxidative stress. Oxidative stress and inflammation should be considered to play a role in the pathophysiology of canine OA.

## DEDICATION

I would like to dedicate this research to my parents, Don and Vickie Dycus, as well as my wife and daughter Brooke and Kennedy Dycus for their faithful support of my pursuit of education.

## ACKNOWLEDGEMENTS

I would like to thank Drs. Ron McLaughlin and Jennifer Wardlaw for giving me an opportunity to pursue surgical residency training and for their time, patience, and contributions to this research project. Furthermore, I would like to thank Dr. Carmelita Frondoza for her assistance and mentorship, Dr. Angela Au, and Mark Grzanna for their assistance and expertise along with Dr. Reinhard Grzanna for help with immuno-cytochemical experiments and analyses. I would also like to thank Drs. Bob and Todd Henderson, as well as Nutramax Laboratories in Edgewood Maryland for funding of this project and allowing me the ability to use their facility to conduct the research.

## TABLE OF CONTENTS

DEDICATION .....	ii
ACKNOWLEDGEMENTS .....	iii
LIST OF FIGURES .....	vi
CHAPTER	
I. INTRODUCTION .....	1
Background .....	1
Osteoarthritis .....	3
Role of inflammation in OA .....	4
Role of oxidative stress in OA .....	8
Management of OA: Pharmacologic and Non-Pharmacologic Treatment Approaches .....	10
References .....	11
II. MODULATION OF INFLAMMATION AND OXIDATIVE STRESS IN CANINE CHONDROCYTES .....	17
Objectives .....	17
Materials and Methods .....	17
Cell Culture .....	17
Experimental Design .....	18
PGE <sub>2</sub> High Sensitivity Immunoassay .....	18
SOD Determination Assay .....	19
GSH Assay .....	19
Phenotype Analysis by Immunohistochemistry .....	19
Statistical Analysis .....	20
Results .....	20
Characterization of canine chondrocyte phenotype .....	20
The effect of oxidative stress on SOD expression in canine chondrocytes .....	20
The effect of oxidative stress on GSH levels in canine chondrocytes .....	21
The effect of cytokines on SOD activity in canine chondrocytes .....	21
The effect of cytokine on PGE <sub>2</sub> production in canine chondrocytes .....	25
Discussion .....	26

Footnotes.....	33
References.....	35
III. CONCLUSION.....	38

## LIST OF FIGURES

1	Immunostaining of canine chondrocytes .....	22
2	Effect of H <sub>2</sub> O <sub>2</sub> on Chondrocyte SOD Activity .....	23
3	Effect of H <sub>2</sub> O <sub>2</sub> on Chondrocyte GSH Levels.....	24
4	Effect of Cytokine Induced Inflammation on Chondrocyte SOD Activity .....	25
5	Effect of Cytokine Induced Inflammation on Chondrocyte PGE <sub>2</sub> Levels.....	27
6	Effect of Cytokine Induced Inflammation on Chondrocyte PGE <sub>2</sub> Levels: 24 hr. activation.....	28
7	Effect of Cytokine Induced Inflammation on Chondrocyte PGE <sub>2</sub> Levels: 48 hr. activation.....	29

# CHAPTER I

## INTRODUCTION

### **Background**

Diarthrodial joints of dogs are highly specialized organs that function to allow repetitive forces to be transmitted along the body in a pain free and frictionless environment (1). The anatomy of a normal diarthrodial joint is composed of a joint capsule, surrounding soft tissues, muscles, and tendons that contribute to the integrity and movement of the joint. Muscle mass further limits joint movement so that it does not exceed anatomical boundaries. Contained in the ligaments, tendons, and muscles are the mechanoreceptors that aid in providing proprioceptive input and fine motor control to prevent injury (2). Therefore, any disruption to the mechanoreceptors (i.e. trauma) will decrease fine motor control and predispose the joint to injury (3). The joint capsule is comprised of two layers, an outer fibrosis layer and an inner subsynovial layer both of which are vascular and innervated. The synovial lining covers every structure in the joint except the cartilage and menisci. Its function is to provide a low friction lining and produce synovial fluid. Synoviocytes make up the synovial lining. Type A synoviocytes are macrophage-like cells and function in phagocytosis. Type B synoviocytes are fibroblast-like and function to produce hyaluronan and enzymes to nourish the chondrocytes. Located throughout the synovium are cells that have immune function, and therefore the synovium contributes to the inflammation that occurs in joint disease (4).

Articular cartilage is a smooth compressible surface that transmits compressive forces across subchondral bone. It functions as a load-bearing cushion within the joint. Chondrocytes help to produce articular cartilage, specifically the extracellular matrix (ECM); they are the only metabolically active component of articular cartilage and have little capability to replicate. This is due to the lack of vascular, nervous, and lymphatic supply. It receives its nutrition from the synovial fluid via diffusion. It is composed of approximately 75-80% water, <5% chondrocytes, and an ECM.

The articular cartilage is composed of approximately 10% proteoglycan matrix, and 10% type II collagen fibers that make up the ECM. The proteoglycan matrix has a hyaluronic acid backbone. Aggrecan is a core protein with glycosaminoglycans attached (GAGS). The aggrecan attaches to hyaluronic acid to form an aggrecan aggregate, which has a gel-like consistency with the ability to hold water. Aggrecan and water provide the compressive stiffness to the tissues whereas collagen provides tensile strength. The proteoglycan matrix is contained within a framework of mainly type II collagen. The collagen forms interlocking loops that provide added support to withstand mechanical forces (5, 6, 7).

Articular cartilage is divided into three zones (zones I to III), which is separated from the calcified cartilage (zone IV) by the tidemark. In adult animals, zone I has the highest cell density. In this zone the chondrocytes are small, flat, and oriented with the long axis parallel to the surface. Zone II is characterized by larger and more rounded cellular profiles while in zone III the chondrocytes are larger but arranged with their long axis approximately perpendicular to the surface (8). The organization of the collagen fibrils complements the cellular arrangement of articular cartilage. In the superficial zone

(zone I) the collagen fibrils are tangential to the articular surface. The middle zone (zone II) has fibrils arranged in an intricate three-dimensional network with many of the fibrils perpendicular to the surface and having branches that fan out. In the deep zone (zone III) and the calcified zone the fibrils are perpendicular and form a more rigid mesh. This organization allows each zone a specific function. In the superficial zone the layer forms a pre-stressed, wear-resistant protective area that can withstand tension in the plane of the articular surface. In contrast the fibrils in zones II and III are organized to provide increased resilience to compressive loading. The concentration of proteoglycan increases with increasing depth from the surface, which means that collagen fibrils are more concentrated at the surface (9).

### **Osteoarthritis**

Osteoarthritis (OA) is a chronic progressive disease affecting diarthrodial joints. Estimates of 20% of middle aged and 90% of older aged dogs are affected by OA (10, 11). OA is a disease affecting the entire joint including: the articular cartilage, bone, and synovium. However, the relationship between the pathology of each of these tissues is poorly understood. Most attention has been focused on the articular cartilage in trying to understand the pathophysiology of OA. Undoubtedly biomechanics play an important role in disease initiation and progression in the articular cartilage, but biomechanical changes occur in all joint tissues. OA is characterized clinically by joint pain, limitation of movement, effusion, and variable degrees of inflammation. Biomechanically, a reduction in proteoglycan concentration, alterations in size of aggregation, increased

water content, collagen fibril disruption, and imbalance in the synthesis and degradation of matrix macromolecules characterize OA (12).

The etiology of OA is not clear. It is proposed that the onset can be the result of an abnormal stress on a normal joint (i.e. trauma, instability) that results from a single event or repetitive microtrauma, or normal stress on an abnormal joint (i.e. genetic (13), infection, inflammation) (1). Regardless of the cause, chondrocyte damage results in a vicious cycle of extracellular matrix destruction; which is the hallmark of OA. This degradation of the cartilage matrix results from an imbalance between chondrocyte catabolic and anabolic events (14, 15, 16).

### **Role of inflammation in OA**

Inflammation of the synovial membrane (synovitis) leads to the production and release of inflammatory mediators from synoviocytes, which are mainly mononuclear cells. A well coordinated system of cytokines and chemokines acts as attractants when receptors have been activated. Chemokines are derived from chemotactic cytokines, which are small heparin binding proteins that were originally defined by their chemotactic activity. They are structurally related to cytokines, whose main function is to regulate cell trafficking (17, 18). They are secreted in response to signals such as proinflammatory cytokines where they have the important role of recruiting monocytes, neutrophils, and lymphocytes (17). Currently in the human literature more than 50 chemokines and 20 chemokine receptors have been identified (19). Chemokines are classified into four subfamilies based on the number and location of the cysteine residues at the N-terminus. The four subfamilies are C-X-C, C-C, and C (20, 21). The C-C and

C-X-C chemokines are further broken into 2 major subgroups. The C-X-C subgroup contains interleukin-8 (IL-8), which will be discussed in detail later. The C-C chemokine family comprises families of monocyte chemoattractant proteins (MCP-1, MCP-2, and MCP-3) as well as others. Chemokines exert their roles by binding to the corresponding G protein-linked cell surface receptors referred to as CXCR or CCR (18). In particular MCP-1 (also known as CCL2) is a potent chemotactic factor for monocytes. MCP-1 recruits monocytes into areas of high inflammation, but the exact signaling pathways still remain unclear. There is evidence to suggest the involvement of prostaglandin E2 (PGE<sub>2</sub>) in the attraction of monocytes to the site of inflammation (22). It is produced by a variety of cell types either at the time of or after the induction by oxidative stress, inflammation (cytokines) growth factors (17), and tumor necrosis factor alpha (TNF- $\alpha$ ), which have been shown to upregulate MCP-1 expression in sensory neurons (23-25). More recently MCP-1 expression has been found in chondrocytes (18). Seitz et al and Volin et al have demonstrated both *in-vivo* and *in-vitro* that synoviocytes from OA patients revealed production of IL-8, MCP-1, and macrophage inflammatory protein-1alpha (MIP-1 $\alpha$ ) (26, 27). Also, it was shown that chemokine receptors in human chondrocytes caused the induction of metalloproteinases (discussed later), which were found to be enhanced in OA chondrocytes (28). This particular study suggests a key role of the chemokine/cytokine receptor system in OA. Furthermore, Yuan et al found that MCP-1 and its receptor CCR2 are expressed in both OA and normal chondrocytes but the response to each was different with the stimulation of interleukin-1 $\beta$  (IL-1 $\beta$ ) and TNF- $\alpha$ . This suggests that the signaling pathways between normal and OA chondrocytes might be different. They were also able to show that proteoglycan synthesis is inhibited by

chemokines (18). MCP-1 is one of the most studied chemokines and has been shown to be a potential intervention point for the treatment of multiple diseases. The idea is that once the signaling pathways of chemokines are more fully understood in OA then treatment can be aimed at blocking the binding of MCP-1 to its receptor site thus damping down the inflammatory response.

Inflammatory cells release a variety of inflammatory mediators such as prostaglandins, leukotrienes, metalloproteinases (14), proteases, free radicals, interleukins (17), tumor necrosis factor (17), and other cytokines. Of particular interest are the roles of interleukin-6, interleukin-8, and IL-1 $\beta$ . IL-6 is a pleiotropic cytokine that has a wide range of roles from immunoregulation, mediation of acute-phase responses, and effects on bone metabolism (29). IL-6 has been suspected in the inflammatory response observed in patients with OA. This is further supported from studies showing that IL-6 knockout mice were resistant to inflammatory arthritis and had reduced levels of serum TNF- $\alpha$  (30). Elevated levels of IL-6 in both serum and synovial fluid of patients with OA seem to correlate with clinical and laboratory indices of disease activity (31). In multiple studies IL-6 is elevated in OA, which is associated with inflammation as well as cartilage and bone destruction (32, 33). Blocking IL-6 with its interactions with the IL-6 receptor (IL-6R) by using IL-6R antagonists reduces cartilage/bone destruction and invasion of cartilage by synovium in animal models and human patients (30, 34).

IL-8 is also produced in arthritic joints by activated synovial cells, and along with IL-6, is considered to be a potent catabolic factor in OA (29). IL-8 induces a massive accumulation of neutrophils, which produce neutrophil elastase. This leads to cartilage destruction. Furthermore, IL-8 injections have been shown to induce the expression of

IL-1 $\beta$  in the joint cavity (35). Several papers have reported that IL-1 $\beta$  is one of the most active catabolic cytokines in OA and plays a pivotal role in the pathogenesis of OA (36-39). As a result of IL-1 $\beta$  release, metalloproteinases such as collagenase-3 (MMP-13) and gelatinase A (MMP-2) are increased as well as production of nitric oxide (NO) which leads to collagen and chondrocyte destruction (15). It was discovered that the free radical, inducible nitric oxide (iNOS), expression in chondrocytes can be induced by a single stimulation of IL-1 $\beta$  or TNF- $\alpha$  while in other types of tissues multiple cytokines are required. The development of OA proinflammatory mediators such as IL-1 $\beta$  and TNF- $\alpha$  not only play a major role at inducing inflammation but also oxidative stress leading to the production of prostaglandins.

Prostaglandins are lipid mediators that have been shown to be locally increased in patients with OA (40). The origination of prostaglandins comes from the insult causing the release of arachidonic acid from the phospholipids of the chondrocytes. Once arachidonic acid is released, it causes the secretion cyclooxygenase and lipoxygenase. Lipoxygenase is responsible for causing the release of leukotrienes, while cyclooxygenase is responsible for the release of different prostaglandins such as PGE<sub>2</sub>, which has catabolic effects on chondrocytes. These catabolic effects result in increased release of other inflammatory mediators such as metalloproteases (MMP's) and IL-1 $\beta$  (41). PGE<sub>2</sub> has also been shown to be involved in multiple conditions such as apoptosis, angiogenesis, structural changes, osteoclastic bone resorption (40), and symptoms of OA (42). It has been noted that cyclooxygenase production (especially COX-2) is up-regulated in both OA and rheumatoid arthritis, thus leading to increased levels of PGE<sub>2</sub> (41). Berenbaum et al discovered that TNF- $\alpha$  would induce cyclooxygenase expression

(especially COX-2) without concurrent release of IL-1 $\beta$  in rabbit chondrocytes; however, both TNF- $\alpha$  and IL-1 $\beta$  act synergistically to cause the release of PGE<sub>2</sub> (43).

### **Role of oxidative stress in OA**

It is proposed that free radical are involved in the pathophysiology of OA. One theory is that oxidative stress and inflammation work synergistically together to cause extracellular matrix destruction. It was shown that MMP's and reactive oxygen species (ROS) are the two main mediators of matrix component degradation (41). However, more is known about inflammation while very little is known about the exact mechanisms oxidative stress plays on canine chondrocytes.

Oxidative stress can be defined as the imbalance of the oxidant-antioxidant ratio where the oxidant outweighs the antioxidant (44). This occurs by the free radicals indiscriminately reacting with molecular oxygen forming ROS (45). Excess ROS such as nitric oxide synthase (NOS), myeloperoxidase (MPO), nitrite, hydroxyl radical, superoxide anions, and hydrogen peroxide attack fatty acids, phospholipids, DNA, and RNA causing cell damage (41, 45). ROS causes damage to DNA by altering nucleic acids by base modification, double base lesions, and strand breaks (44, 45). Yudoh et al found that oxidative stress can induce chondrocyte telomere instability leading to chondrocyte senescence, and a decreased cellular replicative lifespan (46). Molecular oxygen is capable of accepting electrons becoming reduced to superoxide anion which functions as a strong oxidizing agent; but is not stable in aqueous solution and therefore can dismutate to hydrogen peroxide. Hydrogen peroxide is a weaker oxidizing agent than superoxide anion, and acts as an inducer of oxidative stress by interacting with metals such as

copper, Cu (I), and iron, Fe (I) which gives rise to reactive and toxic hydroxyl radicals through the Fenton reaction creating multiple free radicals and thus causing cellular destruction and/or apoptosis (45, 47-49). Multiple studies have proven that inflammation is a key secondary mediator involved with OA, however; only recently has the roles of oxidative stress been addressed in the development and progression of OA. It has been revealed that inflammatory mediators such as IL-1 $\beta$  can induce the production of ROS, along with macrophages, polymorphonuclear leukocytes (50), and chondrocytes (51) but the exact role ROS plays remains unclear. *In vitro* studies further showed that activation with either IL-1 $\beta$  or TNF- $\alpha$  increase iNOS expression in chondrocytes while in other types of tissues multiple cytokines are required (52).

As previously mentioned articular cartilage is an avascular tissue where its nutrients come from synovial fluid and the oxygen tension is only about 1-7% (52, 53). Several studies found that *in vivo* oxygen tension in cartilage is lower than 8%, therefore; chondrocytes have to be able to survive in a low oxygen environment (54, 55). Grimshaw et al found that oxygen tension below 1% will inhibit glucose uptake, lactate production and RNA synthesis, which indicate that some oxygen is needed for chondrocyte metabolic activity (56).

The ability of oxygen to modulate chondrocyte activity is still not fully understood, making it difficult to extrapolate data from other cell types regarding its oxidative response. For example, *in vitro* studies have evaluated the response of oxidative stress in the liver (57) which is a vascular organ receiving 70-80% of cardiac output and having an oxygen tension that is approximately 20-30%. An additional problem is that the self-healing ability of cartilage is severely limited due to its avascularity, lack of

innervation and lymphatic circulation, as well as low cellularity (58). In certain circumstances, oxygen may be transformed into ROS, which plays a role in cellular functions such as cell proliferation, activation, and cell death. Low levels of ROS can act as different secondary messengers in the expression of a wide variety of gene products; however, high levels can lead to cell destruction and death (59, 60).

## **Management of OA: Pharmacologic and Non-Pharmacologic Treatment**

### **Approaches**

A major barrier in managing OA is the fact that it is not a single disease, but rather a disease with different pathophysiological mechanisms that results in damage to type II collagen (14). Multiple therapies have been developed to combat the pathophysiology of OA as well as to relieve pain. Currently a multimodal approach to help decrease inflammation and reduce pain with the use of NSAIDs, intra-articular steroids, oral opioids, omega-3 fatty acids (61-63), polysulfated glycosaminoglycans (64), dietary restriction (65), and chondroprotectants is utilized. Because OA is a chronic and progressive disease new therapies are sought to help decrease the severity of clinical signs. Research has not yet yielded information that identifies any therapeutic modalities to combat oxidative stress in OA such as the use of antioxidants. In human *in vitro* studies oxidative stress and inflammation are reported to work together in the induction of extracellular matrix destruction. Previous studies demonstrated that MMPs and ROS are the two main key participants in matrix component degradation (15).

## References

1. Schmitz N, Kraus VB, Aigner T. Targets to tackle – The pathophysiology of the disease. *Current Drug Targets* 2010;11:521-527.
2. Chikenji T, Suzuki D, Fujimiya M, et al. Distribution of nerve endings in the human proximal interphalangeal joint and surrounding structures. *J Hand Surg Am* 2010;35(8):1286-1293.
3. Delliaux S, Brerro-Saby C, Steinberg JG, et al. Reactive oxygen species and inflammatory mediators enhance muscle spindles mechanosensitivity in rats. *Pflugers Arch* 2009;57(4):877-884.
4. Huss RS, Huddleston JI, Goodman SB, et al. Synovial tissue-infiltration natural killer cells in osteoarthritis and periprosthetic inflammation. *Arthritis Rheum* 2010;62:3799-3805.
5. Todhunter RJ, Johnston SA. Osteoarthritis. In: *Textbook of Small Animal Surgery*, 3<sup>rd</sup> ed, Vol 2. Slatter D (ed). Philadelphia, Elsevier Science 2003; 2208-2246.
6. Henderson B, Pettipher ER. The synovial lining cell: Biology and pathobiology. *Semin Arthritis Rheum* 1985;15:1.
7. Hascall VC, Heinegard D. Aggregation of cartilage proteoglycans: The role of hyaluronic acid. *J Biol Chem* 1974;249:4232.
8. Schenk RK. Articular cartilage morphology. In: *Articular Cartilage Biochemistry*, 1<sup>st</sup> ed, Kuettner KE, et al (eds), New York, Raven Press 1986;3.
9. Seton LA. Altered mechanics of cartilage with osteoarthritis: Human osteoarthritis and an experimental model of joint degeneration. *Osteoarthritis Cartilage* 1999;7:2.
10. Johnston SA. Osteoarthritis. Joint anatomy, physiology, and pathobiology. *Vet Clin North Am Small Anim Pract* 1997;27:699-723.
11. Venable RO, Stoker AM, Cook CR, et al. Examination of synovial fluid hyaluronan quantity and quality in stifle joints of dogs with osteoarthritis. *Am J Vet Res* 2008;69:1569-1573.
12. Mankin HJ, et al. Workshop on etiopathogenesis of osteoarthritis. Proceedings and recommendation. *J Rheumatol* 1986;13:1127.
13. Mateescu RG, Burton-Wurster NI, Tsai K, et al. Identification of quantitative trait loci for osteoarthritis of hip joints in dogs. *Am J Vet Res* 2008;69:1294-1300.

14. Prink A, Hayashi K, Kim SY, et al. Evaluation of collagenase generated osteoarthritis biomarker in the synovial fluid from elbow joints of dogs with medial coronoid disease and unaffected dogs. *Vet Surg* 2009;39:65-70.
15. Henrotin Y, Kurz B, Aigner T. Oxygen and reactive oxygen species in cartilage degradation: friend or foes: *Osteoarthritis Cartilage* 2005;13:643-654.
16. Martin G, Andriamanalijaona R, Mathy-Hartert M, et al. Comparative effects of IL-1 beta and hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) on catabolic and anabolic gene expression in juvenile bovine chondrocytes. *Osteoarthritis Cartilage* 2005;13:915-924.
17. Jung H, Miller RJ. Activation of the nuclear factor of activated T cells (NFAT) mediates upregulation of CCR2 chemokine receptors in dorsal root ganglion (DRG) neurons: A possible mechanism for activity-dependent transcription in DRG neurons in association with neuropathic pain. *Mol Cell Neurosci* 2008;37:170-177.
18. Seitz M, Loetscher P, Dewald B, et al. Production of interleukin-1 receptor antagonist, inflammatory chemotactic proteins and prostaglandin E by rheumatoid and osteoarthritic synoviocytes: regulation by IFN-gamma and IL-4. *J Immunol* 1994;152:2060-2065.
19. Volin MV, Shan MR, Tokuhira M, et al. RANTES expression and contribution to monocyte chemotaxis in arthritis. *Clin Immunol Immunopathol* 1998;89:44-53.
20. Borzi RM, Mazzetti I, Cattini L, et al. Human chondrocytes express functional chemokine receptors and release matrix-degrading enzymes in response to C-X-C and C-C chemokines. *Arthritis Rheum* 2000;43:1734-1741.
21. Rasheed Z, Akhtar N, Haqqi TM. Advanced glycation end products induce the expression of interleukin-6 and interleukin-8 by receptor for advanced glycation end product-mediated activation mitogen-activated protein kinases and nuclear factor- $\kappa$ B in human osteoarthritis chondrocytes. *Rheumatology* 2010;48:1-14.
22. Alonzi T, Fattori E, Lazzaro D, et al. Interleukin 6 is required for the development of collagen-induced arthritis. *J Exp Med* 1998;187:461-468.
23. Houssiau Fa, Devogelaer JP, Van Damme J, et al. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritis. *Arthritis Rheum* 1988;31:784-788.
24. Fonseca JE, Santos MJ, Canhao H, et al. Interleukin-6 as a key player in systemic inflammation and joint destruction. *Autoimmun Rev* 2009;8:538-542.

25. Sakao K, Takahashi KA, Arai Y, et al. Osteoblasts derived from osteocytes produce interleukin-6, interleukin-8, and matrix metalloproteinase-13 in osteoarthritis. *J Bone Miner Metab* 2009;27:412-423.
26. Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6-receptor antibody: a multicenter, double-blind, placebo-controlled trial. *Arthritis Rheum* 2004;50:1761-1769.
27. Matsukawa A, Yoshimura T, Maeda T, et al. Neutrophil accumulation and activation by homologous IL-8 in rabbits. IL-8 induces destruction of cartilage and production of IL-1 and IL-1 receptor antagonist in vivo. *J Immunol* 1995;154:5418-5425.
28. Bruin T, Rooster H, Bree, H. Cytokine mRNA expression in synovial fluid of affected and contralateral stifle joints and the left shoulder joint in dogs with unilateral disease of the stifle joint. *Am J Vet Res* 2007;68:953-961.
29. Rasheed Z, Akhtar N, Haqqi TM. Advanced glycation end products induce the expression of interleukin-6 and interleukin-8 by receptor for advanced glycation end product-mediated activation mitogen-activated protein kinases and nuclear factor- $\kappa$ B in human osteoarthritis chondrocytes. *Rheumatology* 2010;48:1-14.
30. Alonzi T, Fattori E, Lazzaro D, et al. Interleukin 6 is required for the development of collagen-induced arthritis. *J Exp Med* 1998;187:461-468.
31. Houssiau Fa, Devogelaer JP, Van Damme J, et al. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritis. *Arthritis Rheum* 1988;31:784-788.
32. Fonseca JE, Santos MJ, Canhao H, et al. Interleukin-6 as a key player in systemic inflammation and joint destruction. *Autoimmun Rev* 2009;8:538-542.
33. Sakao K, Takahashi KA, Arai Y, et al. Osteoblasts derived from osteocytes produce interleukin-6, interleukin-8, and matrix metalloproteinase-13 in osteoarthritis. *J Bone Miner Metab* 2009;27:412-423.
34. Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of rheumatoid arthritis with humanized anti-interleukin-6-receptor antibody: a multicenter, double-blind, placebo-controlled trial. *Arthritis Rheum* 2004;50:1761-1769.
35. Matsukawa A, Yoshimura T, Maeda T, et al. Neutrophil accumulation and activation by homologous IL-8 in rabbits. IL-8 induces destruction of cartilage and production of IL-1 and IL-1 receptor antagonist in vivo. *J Immunol* 1995;154:5418-5425.

36. Bruin T, Rooster H, Bree, H. Cytokine mRNA expression in synovial fluid of affected and contralateral stifle joints and the left shoulder joint in dogs with unilateral disease of the stifle joint. *Am J Vet Res* 2007;68:953-961.
37. Martin G, Andriamanalijaona R, Grassel S, et al. Effect of hypoxia and reoxygenation on gene expression and response to interleukin-1 in cultured articular chondrocytes. *Arthritis Rheum* 2004;50:3549-3560.
38. Mathy-Hartert M, Burton S, Deby-Dupont G, et al. Influence of oxygen tension on nitric oxide and prostaglandin E2 synthesis by bovine chondrocytes. *Osteoarthritis Cartilage* 2005;13:74-79.
39. Yasuhara R, Miyamoto Y, Akaike T, et al. Interleukin-1beta induces death in chondrocyte-like ATDC5 cells through mitochondrial dysfunction and energy depletion in a reactive nitrogen and oxygen species-dependent manner. *Biochem J* 2005;389:315-323.
40. Amin AR, Attur M, Patel RN, et al. Superinduction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage. Influence of nitric oxide. *J Clin Invest* 1997;99:1231-1237.
41. Alvarez-Soria MA, Largo R, Sanchez-Pernaute O, et al. Prostaglandin E2 receptors EP1 and EP4 are up-regulated in rabbit chondrocytes by IL-1beta, but not by TNFalpha. *Rheumatol Int* 2007;27:911-917.
42. Martel-Pelletier J, Pelletier JP, Fahmi H. Cyclooxygenase-2 and prostaglandins in articular tissues. *Semin Arthritis Rheum* 2003;33:155-167.
43. Berenbaum F, Jacques C, Thomas G, et al. Synergistic effect of interleukin-1 beta and tumor necrosis factor alpha on PGE2 production by articular chondrocytes does not involve PLA2 stimulation. *Exp Cell Res* 1996;222:379-384.
44. Shan X, Chang Y, Glenn Lin C. Messenger RNA oxidation is an early event preceding cell death and causes reduced protein expression. *The FASEB Journal* 2007;21:2753-2764.
45. Pagoria D, Lee A, Geurtsen W. The effect of camphorquinone (CQ) and CQ-related photosensitizers on the generation of reactive oxygen species and the production of oxidative DNA damage. *Biomaterials* 2005;26:4091-4099.
46. Yudoh K, Nguyen T, Nakamura H, et al. Potential involvement of oxidative stress in cartilage senescence and development of osteoarthritis: oxidative stress induces chondrocyte telomere instability and downregulation of chondrocyte function. *Arthritis Res Ther* 2005;7:R380-391.

47. Lee S, Pagoria D, Raigrodski A, et al. Effects of combinations of ROS scavengers on oxidative DNA damage caused by visible-light-activated camphorquinone/N,N-dimethyl-p-toluidine. *J Biomed Mater Res B Appl Biomater* 2007;83:391-399.
48. Milne L, Nicotera P, Orrenius S, et al. Effects of glutathione and chelating agents on copper-mediated DNA oxidation: pro-oxidant and antioxidant properties of glutathione. *Arch Biochem Biophys* 1993;304:102-109.
49. Thannickal VJ, Fanburg BL. Reactive oxygen species in cell signaling. *Am J Physiol Lung Cell Mol Physiol* 2000;279:L1005-1028.
50. Burkhardt H, Schwingel M, Menninger H, et al. Oxygen radicals as effectors of cartilage destruction. Direct degradative effect on matrix components and indirect action via activation of latent collagenase from polymorphonuclear leukocytes. *Arthritis Rheum* 1986;29:379-387.
51. Hiran TS, Moulton PJ, Hancock JT. In situ detection of superoxide anions within porcine articular cartilage. *Br J Biomed Sci* 1998;55:199-203.
52. Falchuk KH, Goetzl EJ, Kulka JP. Respiratory gases of synovial fluids. An approach to synovial tissue circulatory-metabolic imbalance in rheumatoid arthritis. *Am J Med* 1970;49:223-231.
53. Mathy-Hartert M, Hogge L, Sanchez C, et al. Interleukin-1 $\beta$  and interleukin-6 disturb the antioxidant enzyme system in bovine chondrocytes: a possible explanation for oxidative stress generation. *Osteoarthritis and Cartilage* 2008;16:756-763.
54. Brighton CT, Heppenstall RB. Oxygen tension in zones of the epiphyseal plate, the metaphysis and diaphysis. An in vitro and in vivo study in rats and rabbits. *J Bone Joint Surg Am* 1971;53:719-728.
55. Rajpurohit R, Koch CJ, Tao Z, et al. Adaptation of chondrocytes to low oxygen tension: relationship between hypoxia and cellular metabolism. *J Cell Physiol* 1996;168:424-432.
56. Grimshaw M, Mason R. Bovine articular chondrocyte function in vitro depends upon oxygen tension. *Osteoarthritis Cartilage* 2000;8:386-392.
57. Au AY, Hasenwinkel JM, Frondoza CG. Silybin inhibits interleukin-1 $\beta$ -induced production of pro-inflammatory mediators in canine hepatocyte cultures. *J vet Pharmacol Therap* 2010.
58. Hauschild G, Muschter N, Richter A, et al. Cartilage replacement in dogs -- A preliminary investigation of colonization of ceramic matrices. *Vet Comp Orthop Traumatol* 2009;22:216-221.

59. Clancy RM, Gomez PF, Abramson SB. Nitric oxide sustains nuclear factor kappaB activation in cytokine-stimulated chondrocytes. *Osteoarthritis Cartilage* 2004;12:552-558.
60. Lo YC, JA, Grinstein S, Cruz T. Interleukin-1 beta induction of c-fos and collagenase expression in articular chondrocytes; involvement of reactive oxygen species. *J Cell Biochem* 1998;69:19-29.
61. Huck JL, Biery DN, Lawler DF, et al. A longitudinal study of the influence of lifetime food restriction on development of osteoarthritis in the canine elbow. *Vet Surg* 2009;38:192-198.
62. Roush JK, Cross AR, Renberg WC, et al. Evaluation of the effects of dietary supplementation with fish oil omega-3 fatty acids on weight bearing in dogs with osteoarthritis. *J Am Vet Med Assoc*;236:67-73.
63. Roush JK, Dodd CE, Fritsch DA, et al. Multicenter veterinary practice assessment of the effects of omega-3 fatty acids on osteoarthritis in dogs. *J Am Vet Med Assoc*;236:59-66.
64. Fujiki M, Shineha J, Yamanokuchi K, et al. Effects of treatment with polysulfated glycosaminoglycan on serum cartilage oligomeric matrix protein and C-reactive protein concentrations, serum matrix metalloproteinase-2 and -9 activities, and lameness in dogs with osteoarthritis. *Am J Vet Res* 2007;68:827-833.
65. Marshall W, Bockstahler B, Hulse D, et al. A review of osteoarthritis and obesity: current understanding of the relationship and benefit of obesity treatment and prevention in the dog. *Vet Comp Orthop Traumatol* 2009;22:339-345.

CHAPTER II  
MODULATION OF INFLAMMATION AND OXIDATIVE STRESS IN CANINE  
CHONDROCYTES

**Objectives**

The objectives of this study are to further investigate how oxidative stress influences the pathophysiology of canine osteoarthritis and to evaluate if the same inflammatory mediators will cause not only an inflammatory response but also an oxidative stress response. Additionally, an insight into the ability of an antioxidant (N-acetyl-cysteine) to counter-act the influence of oxidative stress was sought. Our hypotheses are: (1) canine chondrocytes will respond to the oxidative stressor hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>), (2) canine chondrocytes will exhibit an oxidative stress and inflammatory response to the inflammatory cocktail of interleukin-1 beta (IL-1 $\beta$ ) and tumor necrosis factor-alpha (TNF- $\alpha$ ), and (3) the oxidative stress induction can be inhibited with an antioxidant.

**Materials and Methods**

**Cell Culture**

Articular cartilage was harvested from canine stifle joints and aseptically diced into <5 mm pieces. The cartilage was digested with type II collagenase (110 U/ml)<sup>a</sup> for 12-18 hours at 37°C in 5% CO<sub>2</sub>. Chondrocytes were filtered through a wire mesh screen

to remove debris and rinsed four times with Hank's Balanced Salt Solution<sup>b</sup>. Cells were counted and assessed for viability using the Trypan-blue exclusion method, and propagated in monolayer culture until confluency in canine chondrocyte media<sup>c</sup>.

### **Experimental Design**

Chondrocytes ( $5 \times 10^5$ ) were seeded onto 6-well plates and maintained at 37°C with 5% CO<sub>2</sub> for 24 hrs. To assess induction of oxidative stress cells were incubated for 24 hours with: (1) canine chondrocyte media, (2) H<sub>2</sub>O<sub>2</sub> at 100, 200, or 300 μM, or (3) a cytokine cocktail of IL-1β (10 ng/ml) and TNF-α (1 ng/ml). To determine if this induction could be inhibited, selected wells were pre-incubated for 24 hours with N-acetyl-cysteine (NAC) at 10 mM before exposure to H<sub>2</sub>O<sub>2</sub>. The effect of cytokines on chondrocyte inflammation was tested by incubating cells with control media alone or with IL-1β (10 ng/ml) and TNF-α (1 ng/ml) for 24 hours. Supernatants and lysates were frozen at -80°C for further analysis of PGE<sub>2</sub> or measurement of SOD enzyme activity and GSH levels.

### **PGE<sub>2</sub> High Sensitivity Immunoassay**

A commercially available PGE<sub>2</sub> immunoassay<sup>d</sup> kit was used to quantify secreted PGE<sub>2</sub> levels in the cellular supernatant, according to the manufacturer's instructions. A PGE<sub>2</sub> standard was run in parallel to the supernatant samples in parallel with triplicate samples. Optical density was measured immediately following incubation using the SpectraMAX 340 microplate reader<sup>e</sup> at 450 nm with wavelength correction set at 540 nm.

### **SOD Determination Assay**

A commercial SOD kit<sup>f</sup> was used to quantify secreted SOD activity (% inhibition rate) in the cell lysate, according to the manufacturer's instructions. An SOD activity standard was run in parallel to the lysate samples using 20 $\mu$ L of each standard and samples were plated onto a 96 well plate<sup>g</sup> in triplicates. The plates were then incubated at 37°C for 20 minutes. Optical density was measured immediately using the SpectraMAX 340 microplate reader<sup>e</sup> at 450 nm.

### **GSH Assay**

The GSH assay was modified from Prieto-Sagredo (1), et al using 0.1 M Sodium Phosphate-0.005 M EDTA Buffer: pH = 8, 0.1% w/v *o*-phthalaldehyde (OPT), and 200  $\mu$ g/ml glutathione stock were all prepared according to authors description. GSH standards were run in parallel to the lysate samples. Optical density was measured immediately using the SpectraMAX Gemini XS microplate reader<sup>e</sup> set at excitation 350 nm and emission 420 nm.

### **Phenotype Analysis by Immunohistochemistry**

Chondrocytes were plated on microscope slides and fixed with 10% v/v paraformaldehyde and immunostained as previously described (2,3). Briefly, slides were incubated with goat anti-type I collagen, anti-type II collagen, or anti-aggrecan antibodies<sup>h</sup>. The slides were next washed in phosphate buffered saline<sup>i</sup> three times and

incubated with FITC labeled anti-goat antibodies. Immunostaining was visualized using a Nikon Eclipse epifluorescent microscope TE200.

### **Statistical Analysis**

Data is presented as the mean  $\pm$  SD. Pair-wise multiple comparisons were carried out using one-way ANOVA, Tukey post-hoc using SigmaStat statistical software (Windows Version 3.11) where  $p < 0.05$  was considered statistically significant. The Sigma Stat program verified that our data is compatible with the assumptions of Normality- Gaussian distribution and homogenous variance.

## **Results**

### **Characterization of canine chondrocyte phenotype**

The majority of cultured canine chondrocytes immunostained for type II collagen. A few cells were shown to immunostain for both type II collagen and type I collagen while an insignificant number immunostained with type I collagen alone (Figure 1). All cells immunostained for aggrecan. This observation indicates that most of the chondrocytes studied maintained features of their original phenotype of articular cartilage in the joint.

### **The effect of oxidative stress on SOD expression in canine chondrocytes**

The chondrocytes exposed to 100, 200, and 300  $\mu\text{M}$  of  $\text{H}_2\text{O}_2$  revealed depletion of SOD activity compared to the chondrocytes cultured in control media alone ( $p < 0.001$  for all 3 concentrations, Figure 2). Pre-treatment with 10mM NAC followed by incubation

with 100, 200, or 300  $\mu\text{M}$   $\text{H}_2\text{O}_2$  significantly increased SOD activity when compared to the activated chondrocytes alone ( $p < 0.001$ ,  $p = 0.001$ ,  $p = 0.003$ , respectively, Figure 2). There was no significant difference in the SOD activity between the control media and the cells pre-treated with NAC followed by activated with any concentration of  $\text{H}_2\text{O}_2$  (Figure 2).

### **The effect of oxidative stress on GSH levels in canine chondrocytes**

Activation with 100, 200, or 300  $\mu\text{M}$  of  $\text{H}_2\text{O}_2$  decreased GSH levels; however, this was not significant when compared to the chondrocytes cultured in control media alone (Figure 3). Pre-treatment with 10mM NAC followed by activation with 100, 200, or 300  $\mu\text{M}$   $\text{H}_2\text{O}_2$  significantly increased GSH levels when compared to the activated chondrocytes ( $p < 0.001$  for all three  $\text{H}_2\text{O}_2$  concentrations, Figure 3) and control media ( $p < 0.001$  for all three  $\text{H}_2\text{O}_2$  concentrations respectively, Figure 3).

### **The effect of cytokines on SOD activity in canine chondrocytes**

Chondrocytes cultured with the control media alone showed higher levels of SOD activity compared to cytokine-activated chondrocytes (Figure 4). The chondrocytes activated with a cocktail of 10 ng/ml IL-1 $\beta$  and 1 ng/ml TNF- $\alpha$  revealed significantly decreased levels of SOD activity at 24 and 48 hour activation compared to the chondrocytes cultured in control media alone ( $p < 0.001$ , and  $p = 0.026$ , respectively, Figure 4). The response was time-dependent with a significantly greater decrease noted 48 hours post activation (Figure 4).




Figure 1

Immunostaining of canine chondrocytes

Immunostaining of canine chondrocytes showing few cells staining for collagen type I (red), while the majority of cells stain for collagen type II (green)




Figure 2

### Effect of H<sub>2</sub>O<sub>2</sub> on Chondrocyte SOD Activity

SOD activity in response to H<sub>2</sub>O<sub>2</sub> concentrations (100, 200, 300 μM) and NAC (10 mM) in canine chondrocytes lysates (mean ± SD). H<sub>2</sub>O<sub>2</sub> completely depleted SOD activity.

\*Mean SOD values were statistically significant when incubated with H<sub>2</sub>O<sub>2</sub> (p<0.001 for 100, 200 and 300 μM H<sub>2</sub>O<sub>2</sub>) compared to control (C). \*\*Treatment with NAC significantly increased SOD values (p<0.001 for 100, 200 μM, p=0.003 for 300 μM H<sub>2</sub>O<sub>2</sub>) compared to cells activated with H<sub>2</sub>O<sub>2</sub> alone




Figure 3

### Effect of H<sub>2</sub>O<sub>2</sub> on Chondrocyte GSH Levels

Intracellular GSH levels following exposure to H<sub>2</sub>O<sub>2</sub> concentrations (100, 200, 300 μM) and NAC (10 mM) (mean ± SD). \*Mean GSH levels decreased when activated with all concentrations of H<sub>2</sub>O<sub>2</sub> compared to controls (C); however this response was not significant. \*\*Treatment with NAC significantly increased GSH values (p<0.001 for 100, 200, and 300 μM H<sub>2</sub>O<sub>2</sub>) compared to activated cells and compared to control (p<0.001 for 100, 200, and 300 μM H<sub>2</sub>O<sub>2</sub>)




Figure 4

#### Effect of Cytokine Induced Inflammation on Chondrocyte SOD Activity

SOD activity in canine chondrocyte cellular lysate (mean  $\pm$  SD) following 24 and 48 hr activation. Mean SOD activity levels are shown as percent of cytokine activated control.

\*Mean values were statistically significant ( $p \leq 0.001$  for 24 hr,  $p = 0.026$  for 48 hr)

compared to control values (C)

#### The effect of cytokine on PGE<sub>2</sub> production in canine chondrocytes

Cytokines IL-1 $\beta$  and TNF- $\alpha$  are well known pro-inflammatory mediators and induced the production of PGE<sub>2</sub>. Chondrocytes activated with a cocktail of 10 ng/ml IL-1 $\beta$  and 1 ng/ml TNF- $\alpha$  for 24 and 48 hours exhibited significantly increased levels of PGE<sub>2</sub> when compared to the chondrocytes cultured in control media alone ( $p < 0.001$  and

p=0.010 respectively, Figure 5). No statistically significant difference was noted between the chondrocytes at the 24 and 48-hour activation periods, but PGE<sub>2</sub> levels were slightly decreased at 48 hours (Figure 5). The PGE<sub>2</sub> production was expressed as a percentage of control due to the varying production levels amongst different sets. However, as a whole the trends were noted to be similar (Figures 6 and 7).

## **Discussion**

The principal finding of the present study is that oxidative stress can be inducted with either hydrogen peroxide or cytokines in an *in vitro* canine chondrocyte culture model. Most of the chondrocyte cultures used in the present study immunostained intensely for type II collagen indicating that they maintained features of the cartilage phenotype (Figure 1). We then showed that H<sub>2</sub>O<sub>2</sub> or cytokines induce an oxidative stress response as demonstrated by a decrease in intracellular SOD (Figures 2 and 4). Similar to earlier findings our results also show that chondrocytes respond to cytokine activation, reflected by a marked increase in PGE<sub>2</sub> production (Figure 5). These findings are consistent with other published data in humans where oxidative stress has been implicated in the progression and development of OA (4-7).




Figure 5

Effect of Cytokine Induced Inflammation on Chondrocyte PGE<sub>2</sub> Levels

PGE<sub>2</sub> levels (ng/ml) in canine chondrocyte supernatant (mean  $\pm$  SD) following 24 and 48 hr cytokine activation expressed as percent of cytokine activated controls. Mean PGE<sub>2</sub> levels released into the cellular supernatant are shown as percent of activated control.

\*Mean values were statistically significant ( $p < 0.001$  for 24 hr,  $p < 0.01$  for 48 hr) compared to control values (C)




Figure 6

Effect of Cytokine Induced Inflammation on Chondrocyte PGE<sub>2</sub> Levels: 24 hr. activation  
Representative PGE<sub>2</sub> levels in 3 separate runs to show differences in concentration  
between canine chondrocyte cell lines following 24 hr. cytokine activation




Figure 7

Effect of Cytokine Induced Inflammation on Chondrocyte PGE<sub>2</sub> Levels: 48 hr. activation  
 Representative PGE<sub>2</sub> levels in 3 separate runs to show differences in concentration  
 between canine chondrocyte cell lines following 48 hr. cytokine activation

The observations in the present study identified mediators known to be involved in the development of OA. Proinflammatory mediators such as IL-1 $\beta$  and TNF- $\alpha$  play a major role at inducing both inflammation and oxidative stress leading to the production of prostaglandins, particularly PGE<sub>2</sub>. Production of this lipid mediator has been shown to be increased in the joints of patients with OA (8). PGE<sub>2</sub> has catabolic effects on chondrocytes, which result in increased release of other inflammatory mediators such as MMPs and IL-1 $\beta$  (9). PGE<sub>2</sub> has also been shown to be involved in multiple conditions such as apoptosis, angiogenesis, structural changes, and osteoclastic bone resorption (8), which are displayed in OA (10). Cyclooxygenase-2, the key enzyme that controls PGE<sub>2</sub>

production is upregulated by TNF- $\alpha$  (11). IL-1 $\beta$  and TNF- $\alpha$  induced inflammation in our chondrocyte cultures in agreement with other studies in showing that PGE<sub>2</sub> levels significantly increase with activation (Figure 5) (8, 12, 13).

The present study showed that SOD levels can be induced using three different concentrations of H<sub>2</sub>O<sub>2</sub> (Figure 2). Depleted stores of SOD secondary to increased levels of ROS may help explain this observation. Overtime SOD could possibility be exhausted, thereby removing one of the first lines of defense against ROS, which may lead to cellular damage and apoptosis. The role of ROS and SOD has been implicated in clinical studies such as those of Scott et al who reported diminished SOD levels during end stage OA in human cartilage (14).

To prevent toxicity/cell death by ROS, chondrocytes are thought to have a well-coordinated antioxidant enzyme system consisting of SOD, catalase, and GPX. SOD transforms superoxide anion into H<sub>2</sub>O<sub>2</sub> and oxygen. SOD plays an important role in managing ROS but is also very limited because H<sub>2</sub>O<sub>2</sub> can still cause oxidative stress if other detoxification enzymes (i.e. GPX, catalase) are ineffective or depleted (15). We chose to use SOD as a biomarker of oxidative stress because it is the most abundant antioxidant available both intracellularly and extracellularly. During inflammation and/or oxidative stress, oxidative defense genes (i.e. SOD) are reported to be down-regulated in multiple tissues including astrocytes and chondrocytes (6, 16, 17). SOD has been discovered in three isoforms in humans. SOD1 (Cu/Zn-SOD) is found in the cytoplasm, nucleus, and intermembrane space of mitochondria. In the mouse model SOD1 mutations are associated with increased apoptosis and oxidative protein damage, and play a central role in cell survival (18). Overproduction of the inflammatory marker, TNF- $\alpha$ , has been

associated with increased oxidative stress consistent with decreases in SOD1 expression (19). TNF- $\alpha$  suppresses SOD1 production may explain the generation of superoxide anion. This also suggests its involvement in inflammatory and oxidative stress conditions as was shown in this study (18). SOD2 is found in the mitochondria and has been shown to provide a pivotal role against ROS generated by hyperoxia. Inflammatory cytokines such as IL-1 $\beta$  and TNF- $\alpha$  are well known activators of SOD2, which also contains sites that bind to NF- $\kappa$ B (20). ROS may induce transcription factors binding activity and can then act as secondary messengers of cytokines (21). SOD3 (EC-SOD) is found in the extracellular space; both isoforms (SOD1 and SOD3) use copper and zinc as cofactors. SOD3 has a strong affinity for proteoglycans in the ECM. Its main function is to protect cells and the ECM against the effects of superoxide anion (18). SOD2 has been shown to be down-regulated in OA while SOD3 is decreased in human OA and a mouse model of OA (16, 22, 23). Recently Scott et al found that all three SOD family members (SOD1, SOD2, and SOD3) were down regulated in diseased cartilage. It was shown in Hartley guinea pigs that down-regulation of SOD2 precedes the development of OA lesions raising the suspicion that SOD2 expression may be associated with the earliest stages of OA (14). Our results are consistent with these reports showing decreased levels of SOD in states of increased oxidative stress and inflammation (Figures 2 and 4).

Although not statistically significant, our results indicate that GSH levels tend to decrease upon exposure to H<sub>2</sub>O<sub>2</sub> (Figure 3). It may be possible that SOD levels are exhausted prior to glutathione being activated. However, little is known about GSH in response to oxidants in chondrocytes. It would be informative if future research could focus on both isoforms of glutathione (oxidized and reduced), and evaluate their

expression in relation to acute and chronic oxidative stress in canine chondrocytes. Glutathione is one of the most abundant cellular antioxidants (24), it serves as a substrate for enzymes such as glutathione peroxidase which neutralizes  $H_2O_2$  and other peroxides during oxidative stress (25). Glutathione has been shown to be an effective  $ONOO^-$  scavenger (26). A portion of the glutathione system is glutathione reductase, and its two forms: GSH, and GSSG, which play a primary role in detoxifying  $H_2O_2$  and other peroxides to water and oxygen (27). During oxidative stress, glutathione reductase regenerates GSH from GSSG using NADPH. This activity was reported to prevent GSSG from leaving the cell and creating a GSH depletion environment, which can favor apoptosis (25, 28).

Under known oxidative stressors and glutathione depletion, cell death was significantly increased. In conditions where GSH was abundant, the chondrocytes were protected from the same oxidative stressors (25). This protection could occur as increased levels of GSH serve as a substrate for the glutathione peroxidase pathway thus eliminating  $H_2O_2$  and other toxic peroxides (29). Studies have shown that apoptotic cell death is found in chondrocytes in articular cartilage of both OA and rheumatoid arthritis patients (25). It was proposed that chondrocytes may have been deprived of GSH, and are thus more prone to oxidative stress. These cells may be unable to detoxify or scavenge different ROS (28). Reduced levels of GSH can have damping effects on the production of cartilage extracellular matrix components. Because of GSH depletion, dysregulated production of ROS could reduce the production of proteoglycan and hyaluronic acid (29,30).

The present study also showed that NAC inhibited oxidative stress in our stressed chondrocyte cultures (Figures 2 and 3). This is reminiscent of Ueno's study where treatment with NAC not only restored GSH, but also increased the glutathione reserves (31). The exact mechanism for this observation is unknown, but may be due to rapid depletion and inability to rapidly regenerate SOD stores. NAC may help keep the SOD expression from becoming completely depleted. In contrast, GSH expression is not readily exhausted, and therefore the NAC not only maintains GSH levels to prevent apoptosis, but also gives a protective effect by increasing GSH stores. Another possible explanation is that NAC could serve as a substrate to help replenish or maintain GSH levels. Currently, only a few antioxidants have been explored for the management of oxidative stress in response to chondrocyte damage. NAC has been shown to protect temporo-mandibular chondrocytes from oxidative stress by fully restoring viability and function of chondrocytes and increasing glutathione reserves in the presence of H<sub>2</sub>O<sub>2</sub> (31.)

A major limitation to our study is that using an *in vitro* model does not recapitulate every condition *in vivo*. However, this canine chondrocyte culture model provided a useful tool to show that oxidative stress can be induced with H<sub>2</sub>O<sub>2</sub> or the combination of IL-1 $\beta$  and TNF- $\alpha$ .

### **Footnotes**

<sup>a</sup> Gibco Invitrogen, Carlsbad, CA, USA

<sup>b</sup> ATCC; Manassas, VA, USA

<sup>c</sup> Cell Applications, Inc; San Diego, CA, USA

- <sup>d</sup> R&D Systems, Minneapolis, MN, USA
- <sup>e</sup> Molecular Devices, Sunnyvale, CA, USA
- <sup>f</sup> Sigma-Aldrich, St. Louis, MO, USA
- <sup>g</sup> Corning Costar, Corning NY, USA
- <sup>h</sup> Southern Biotechnology Associates; Birmingham, AL USA
- <sup>i</sup> PBS, Gibco Invitrogen, Carlsbad, CA, USA

## References

1. Prieto-Sagredo J, Ricalde-Recchia I, Duran-Lizarraga ME, et al. Changes in hemolymph glutathione status after variation in photoperiod and light-irradiance in crayfish *Procambarus clarkii* and *Procambarus digueti*. *Photochem Photobiol* 2000;71:487-492.
2. Heinecke LF, Grzanna MW, Au AY, et al. Inhibition of cyclooxygenase-2 expression and prostaglandin E2 production in chondrocytes by avocado soybean unsaponifiables and epigallocatechin gallate. *Osteoarthritis Cartilage* 2010;18:220-227.
3. Frondoza CG, Heinecke LF, Grzanna MW, et al. Modulation of cytokine-induced prostaglandin E production in cultures of articular chondrocytes obtained from carpal joints of camels (*Camelus dromedarius*). *Am J Vet Res* 2011;72:51-58.
4. Pagoria D, Lee A, Geurtsen W. The effect of camphorquinone (CQ) and CQ-related photosensitizers on the generation of reactive oxygen species and the production of oxidative DNA damage. *Biomaterials* 2005;26:4091-4099.
5. Mathy-Hartert M, Hogge L, Sanchez C, et al. Interleukin-1beta and interleukin-6 disturb the antioxidant enzyme system in bovine chondrocytes: a possible explanation for oxidative stress generation. *Osteoarthritis Cartilage* 2008;16:756-763.
6. Davies CM, Guilak F, Weinberg JB, et al. Reactive nitrogen and oxygen species in interleukin-1-mediated DNA damage associated with osteoarthritis. *Osteoarthritis Cartilage* 2008;16:624-630.
7. Lee S, Pagoria D, Raigrodski A, et al. Effects of combinations of ROS scavengers on oxidative DNA damage caused by visible-light-activated camphorquinone/N,N-dimethyl-p-toluidine. *J Biomed Mater Res B Appl Biomater* 2007;83:391-399.
8. Amin AR, Attur M, Patel RN, et al. Superinduction of cyclooxygenase-2 activity in human osteoarthritis-affected cartilage. Influence of nitric oxide. *J Clin Invest* 1997;99:1231-1237.
9. Alvarez-Soria MA, Largo R, Sanchez-Pernaute O, et al. Prostaglandin E2 receptors EP1 and EP4 are up-regulated in rabbit chondrocytes by IL-1beta, but not by TNFalpha. *Rheumatol Int* 2007;27:911-917.
10. Martel-Pelletier J, Pelletier JP, Fahmi H. Cyclooxygenase-2 and prostaglandins in articular tissues. *Semin Arthritis Rheum* 2003;33:155-167.
11. Berenbaum F, Jacques C, Thomas G, et al. Synergistic effect of interleukin-1 beta and tumor necrosis factor alpha on PGE2 production by articular chondrocytes does not involve PLA2 stimulation. *Exp Cell Res* 1996;222:379-384.

12. Geng Y, Blanco FJ, Cornelisson M, et al. Regulation of cyclooxygenase-2 expression in normal human articular chondrocytes. *J Immunol* 1995;155:796-801.
13. Palmer RM, Hickery MS, Charles IG, et al. Induction of nitric oxide synthase in human chondrocytes. *Biochem Biophys Res Commun* 1993;193:398-405.
14. Scott JL, Gabrielides C, Davidson RK, et al. Superoxide dismutase downregulation in osteoarthritis progression and end-stage disease. *Ann Rheum Dis*;69:1502-1510.
15. Henrotin Y, Kurz B, Aigner T. Oxygen and reactive oxygen species in cartilage degradation: friends or foes? *Osteoarthritis Cartilage* 2005;13:643-654.
16. Aigner T, Fundel K, Saas J, et al. Large-scale gene expression profiling reveals major pathogenetic pathways of cartilage degeneration in osteoarthritis. *Arthritis Rheum* 2006;54:3533-3544.
17. Sharma V, Mishra M, Ghosh S, et al. Modulation of interleukin-1beta mediated inflammatory response in human astrocytes by flavonoids: implications in neuroprotection. *Brain Res Bull* 2007;73:55-63.
18. Afonso V, Champy R, Mitrovic D, et al. Reactive oxygen species and superoxide dismutases: role in joint diseases. *Joint Bone Spine* 2007;74:324-329.
19. Afonso V, Santos G, Collin P, et al. Tumor necrosis factor-alpha down-regulates human Cu/Zn superoxide dismutase 1 promoter via JNK/AP-1 signaling pathway. *Free Radic Biol Med* 2006;41:709-721.
20. Kiningham KK, Xu Y, Daosukho C, et al. Nuclear factor kappaB-dependent mechanisms coordinate the synergistic effect of PMA and cytokines on the induction of superoxide dismutase 2. *Biochem J* 2001;353:147-156.
21. Henrotin YE, Bruckner P, Pujol JP. The role of reactive oxygen species in homeostasis and degradation of cartilage. *Osteoarthritis Cartilage* 2003;11:747-755.
22. Ruiz-Romero C, Calamia V, Mateos J, et al. Mitochondrial dysregulation of osteoarthritic human articular chondrocytes analyzed by proteomics: a decrease in mitochondrial superoxide dismutase points to a redox imbalance. *Mol Cell Proteomics* 2009;8:172-189.
23. Regan E, Flannelly J, Bowler R, et al. Extracellular superoxide dismutase and oxidant damage in osteoarthritis. *Arthritis Rheum* 2005;52:3479-3491.
24. Wendell PL. Measurement of oxidized glutathione and total glutathione in the perfused rat heart. *Biochem J* 1970;117:661-665.

25. Carlo MD, Jr., Loeser RF. Increased oxidative stress with aging reduces chondrocyte survival: correlation with intracellular glutathione levels. *Arthritis Rheum* 2003;48:3419-3430.
26. Sies H, Sharov VS, Klotz LO, et al. Glutathione peroxidase protects against peroxynitrite-mediated oxidations. A new function for selenoproteins as peroxynitrite reductase. *J Biol Chem* 1997;272:27812-27817.
27. Bazzichi L, Ciompi ML, Betti L, et al. Impaired glutathione reductase activity and levels of collagenase and elastase in synovial fluid in rheumatoid arthritis. *Clin Exp Rheumatol* 2002;20:761-766.
28. Ghibelli L, Fanelli C, Rotilio G, et al. Rescue of cells from apoptosis by inhibition of active GSH extrusion. *FASEB J* 1998;12:479-486.
29. Baker MS, Feigan J, Lowther DA. Chondrocyte antioxidant defences: the roles of catalase and glutathione peroxidase in protection against H<sub>2</sub>O<sub>2</sub> dependent inhibition of proteoglycan biosynthesis. *J Rheumatol* 1988;15:670-677.
30. Bates EJ, Lowther DA, Johnson CC. Hyaluronic acid synthesis in articular cartilage: an inhibition by hydrogen peroxide. *Biochem Biophys Res Commun* 1985;132:714-720.
31. Ueno T, Yamada M, Sugita Y, et al. N-Acetyl Cysteine Protects TMJ Chondrocytes from Oxidative Stress. *J Dent Res*;90:353-359.

## CHAPTER III

### CONCLUSION

The principal finding of the present study is that oxidative stress can be induced with either hydrogen peroxide or cytokines in an *in vitro* canine chondrocyte culture model. Most of the chondrocyte cultures used in the present study immunostained intensely for type II collagen indicating that they maintained features of the cartilage phenotype. We then showed that H<sub>2</sub>O<sub>2</sub> or cytokines induce an oxidative stress response as demonstrated by a decrease in intracellular SOD. Similar to earlier findings our results also show that chondrocytes respond to cytokine activation, reflected by a marked increase in PGE<sub>2</sub> production. It was also shown that NAC inhibited oxidative stress in our stressed chondrocyte cultures. This *in vitro* model facilitated the study of cellular events involved with oxidative stress and inflammation. This model may be used for additional research to evaluate agents that inhibit oxidative stress and/or inflammation with the goal being to improve clinical management of canine OA.